4D Molecular Therapeutics, Inc. (FDMT) P/S ratio

P/S ratio today
7.3×

4D Molecular Therapeutics, Inc. (FDMT) trades at 7.3× its revenue per share for fiscal 2025. At the end of fiscal 2025 (December 31, 2025) its P/S ratio was 5.1×. Today's figure is 43.9% above the fiscal 2025 year-end. Figures as of 18 Nov 2026, 05:03 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

P/S ratio today
7.3×
P/S ratio, fiscal 2025
5.1×
Highest on record
229.6×fiscal 2022
Lowest on record
5.1×fiscal 2025
Fiscal years on record
42021–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

4D Molecular Therapeutics, Inc. P/S ratio, in more detail

Across the 4 fiscal year-ends on record (2021–2025), the highest was 229.6× in fiscal 2022 and the lowest 5.1× in fiscal 2025. Today's P/S ratio is higher than at 25% of the 4 fiscal year-ends on record; their median is 36.0×.

History · 4 fiscal years

P/S ratio at each fiscal year-end

The last point is today's figure; the others are fiscal year-ends.

4D Molecular Therapeutics, Inc. P/S ratio, year by year

4D Molecular Therapeutics, Inc. (FDMT) P/S ratio by fiscal year
Fiscal yearP/S ratioChangeYear endedShare price at year-endRevenue per share
Today7.3×—$10.79—
20255.1×—$7.50$1.47
2024——$5.57$0.00
202338.3× 83.3% down$20.26$0.53
2022229.6× 580.8% up$22.21$0.10
202133.7×—$21.94$0.65
2020——$41.45—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

The P/S ratio is the share price divided by revenue per share — the same thing as market value divided by revenue — taken at each fiscal year-end.

How to read it

It prices each unit of sales and still works when there is no profit; what counts as high depends on the margin those sales earn.

More on FDMT

4D Molecular Therapeutics, Inc., figure by figure

4D Molecular Therapeutics, Inc. (FDMT) overview: price, valuation and scorecard

4D Molecular Therapeutics, Inc. P/S ratio: questions and answers

What is 4D Molecular Therapeutics, Inc.'s P/S ratio?

4D Molecular Therapeutics, Inc. (FDMT) trades at 7.3× its revenue per share for fiscal 2025. At the end of fiscal 2025 (December 31, 2025) its P/S ratio was 5.1×.

Is 4D Molecular Therapeutics, Inc.'s P/S ratio high or low compared with its own history?

Today's P/S ratio is higher than at 25% of the 4 fiscal year-ends on record; their median is 36.0×.

What are the highest and lowest P/S ratio figures on record for 4D Molecular Therapeutics, Inc.?

Across the 4 fiscal year-ends on record (2021–2025), the highest was 229.6× in fiscal 2022 and the lowest 5.1× in fiscal 2025.

How is 4D Molecular Therapeutics, Inc.'s P/S ratio calculated?

The P/S ratio is the share price divided by revenue per share — the same thing as market value divided by revenue — taken at each fiscal year-end.

Share prices are Yahoo Finance's monthly closes: a fiscal year-end is paired with the close of the month it falls in, and today's quote may be delayed. Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “4D Molecular Therapeutics, Inc. (FDMT) P/S ratio”, data as of 18 November 2026. https://funkfolio.com/stock/FDMT/ps-ratio

Underlying data: the company's filings with the SEC and Yahoo Finance.